Steiner T, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, Hacke W
Department of Neurology, University of Heidelberg, Germany.
Cerebrovasc Dis. 1998 Jul-Aug;8(4):198-203. doi: 10.1159/000015851.
(1) To determine whether and how outcome measurements in the ECASS trial are influenced by a shorter time window (0-3 vs. 3-6 h) between onset of symptoms and start of thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke. (2) To discuss the results of the ECASS 0- to 3-hour cohort with the results of the National Institute of Neurological Disorders and Stroke Study (NINDSS).
Analysis of the 0- to 3-hour and the 3- to 6-hour cohort in accordance with the ECASS protocol. Comparative analysis of the ECASS and NINDSS results following the NINDSS protocol using dichotomized endpoints.
Primary endpoints: modified Rankin Scale, Barthel Index; secondary endpoints: combined Barthel/Rankin, long-term Scandinavian Stroke Scale, National Institutes of Health Stroke Scale, mortality at 30 and 90 days, occurrence of intracranial hemorrhage. NINDS trial endpoint: favorable outcome as defined in the NINDS trial.
In ECASS, 87 patients were randomized within 3 h of stroke onset. Differences in favor of rt-PA treatment can be found for all primary and secondary outcome measures in the ECASS 0- to 3-hour cohort, except for mortality at day 30, which is somewhat higher in the rt-pA-treated group. However, due to the small sample size, the differences do not reach statistical significance. Early infarct signs (as defined by the ECASS protocol) are found as early as 2 h after stroke onset. Parenchymal hemorrhages are found significantly more often among rt-PA-treated patients. The results in the ECASS 0- to 3-hour cohort fit well with the results in NINDSS.
Data from the 3-hour ECASS cohort support the efficacy of early thrombolytic therapy in acute hemispheric stroke patients. Comparing bleeding complications between the ECASS and NINDSS is difficult because of differences in the definition and occurrence of hemorrhagic events.
(1)确定急性缺血性卒中患者症状发作至使用重组组织型纤溶酶原激活剂(rt-PA)进行溶栓治疗开始的较短时间窗(0 - 3小时对比3 - 6小时)是否以及如何影响欧洲急性卒中协作研究(ECASS)试验中的结局测量指标。(2)将ECASS试验中0至3小时队列的结果与美国国立神经疾病与卒中研究所研究(NINDSS)的结果进行讨论。
按照ECASS方案对0至3小时和3至6小时队列进行分析。使用二分终点,按照NINDSS方案对ECASS和NINDSS结果进行对比分析。
主要终点:改良Rankin量表、Barthel指数;次要终点:Barthel/Rankin联合指标、长期斯堪的纳维亚卒中量表、美国国立卫生研究院卒中量表、30天和90天死亡率、颅内出血发生率。NINDS试验终点:NINDS试验中定义的良好结局。
在ECASS试验中,87例患者在卒中发作3小时内随机分组。在ECASS试验0至3小时队列中,除30天死亡率外(rt-PA治疗组略高),所有主要和次要结局测量指标均显示rt-PA治疗更具优势。然而,由于样本量小,差异未达到统计学意义。卒中发作后2小时即可发现早期梗死征象(按照ECASS方案定义)。rt-PA治疗患者中实质性出血的发生率明显更高。ECASS试验0至3小时队列的结果与NINDSS试验结果吻合良好。
ECASS试验3小时队列的数据支持早期溶栓治疗对急性半球性卒中患者的疗效。由于出血事件的定义和发生率存在差异,比较ECASS试验和NINDSS试验中的出血并发症较为困难。